Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/1078-0432.CCR-12-3680 http://scihub22266oqcxt.onion/10.1158/1078-0432.CCR-12-3680 C4058638!4058638!24928944     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Cancer+Res 2014 ; 20 (12): 3057-63 Nephropedia Template TP {{tp|p=24928944|t=2014. Molecular Pathways: PI 3-Kinase Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy |pdf=|usr=}}{{24928944}} gab.com Text Molecular Pathways: PI 3-Kinase Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy JO: Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24928944 #FOAvip Cancer research has seen tremendous changes over the past decade. Fast progress in sequencing technology has afforded us with landmark genetic alterations, which had immediate impact on clinical science and practice by pointing to new kinase targets, such as PI 3-Kinase, the EGF receptor or BRAF. The PI 3-Kinase pathway for growth control has emerged as a prime example for both oncogene activation and tumor suppressor loss in cancer.Here, we discuss how therapy using PI 3-kinase pathway inhibitors could benefit from information on specific phosphatases, which naturally antagonize the kinase targets. This PI 3-Kinase pathway is found mutated in most cancer types, including prostate, breast, colon and brain tumors. The tumor suppressing phosphatases operate at two levels. Lipid level phosphatases, such as PTEN and INPP4b revert PI 3-kinase activity to keep the lipid second messengers inactive. At the protein level, PHLPP1/2 protein phosphatases inactivate AKT kinase, thus antagonizing mTOR complex 2 activity. However, in contrast to their kinase counterparts the phosphatases are unlikely drug targets. They would need to be stimulated by therapy and are commonly deleted and mutated in cancer. Yet, since they occupy critical nodes in preventing cancer initiation and progression, the information on their status has tremendous potential in outcome prediction, and in matching the available kinase inhibitor repertoire with the right patients. Twit Text FOAVip Molecular Pathways: PI 3-Kinase Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy ????Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24928944 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24928944 #FOAvip English Wikipedia <ref>{{Cite pmid|24928944}}</ref> Molecular Pathways: PI 3-Kinase Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy #MMPMID24928944 Chen M; Nowak DG; Trotman LC Clin Cancer Res 2014[Jun]; 20 (12): 3057-63 PMID24928944show ga Cancer research has seen tremendous changes over the past decade. Fast progress in sequencing technology has afforded us with landmark genetic alterations, which had immediate impact on clinical science and practice by pointing to new kinase targets, such as PI 3-Kinase, the EGF receptor or BRAF. The PI 3-Kinase pathway for growth control has emerged as a prime example for both oncogene activation and tumor suppressor loss in cancer.Here, we discuss how therapy using PI 3-kinase pathway inhibitors could benefit from information on specific phosphatases, which naturally antagonize the kinase targets. This PI 3-Kinase pathway is found mutated in most cancer types, including prostate, breast, colon and brain tumors. The tumor suppressing phosphatases operate at two levels. Lipid level phosphatases, such as PTEN and INPP4b revert PI 3-kinase activity to keep the lipid second messengers inactive. At the protein level, PHLPP1/2 protein phosphatases inactivate AKT kinase, thus antagonizing mTOR complex 2 activity. However, in contrast to their kinase counterparts the phosphatases are unlikely drug targets. They would need to be stimulated by therapy and are commonly deleted and mutated in cancer. Yet, since they occupy critical nodes in preventing cancer initiation and progression, the information on their status has tremendous potential in outcome prediction, and in matching the available kinase inhibitor repertoire with the right patients. äMolecular Pathways: PI 3-Kinase Pathway Phosphatases as Biomarkers for(epmc).pdf DeepDyve Pubget Overpricing